Pharmaceutical intervention in the JAK/STAT signaling pathway
Open Access
- 25 May 2000
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 19 (21) , 2645-2656
- https://doi.org/10.1038/sj.onc.1203550
Abstract
Many cytokines exert their effect via the JAK/STAT signal transduction pathway. Due to the medical relevance of many of these cytokines, they are being exploited, either directly, or through antagonists, as therapeutics for a variety of serious diseases. Currently, these therapeutics consist almost entirely of protein products, with all of their attendant drawbacks. Delineation of the signaling mechanisms for the cytokines, however, has allowed the design and implementation of a variety of cell-based and biochemical screens for small molecule mimics or antagonists of these cytokines. Several successful assays will be described along with the advantages of each type of assay. Use of assays of this type should make it possible to discover numerous small molecule cytokine modulators with significant utility in the clinic.Keywords
This publication has 64 references indexed in Scilit:
- A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral SclerosisBiochemical and Biophysical Research Communications, 2000
- Regulation of Transcription by a Protein MethyltransferaseScience, 1999
- Stat6 Is Required for Mediating Responses to IL-4 and for the Development of Th2 CellsPublished by Elsevier ,1996
- Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling PathwayCell, 1996
- Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitorNature, 1996
- Phosphorylation and Activation of the DNA Binding Activity of Purified Stat1 by the Janus Protein-tyrosine Kinases and the Epidermal Growth Factor ReceptorJournal of Biological Chemistry, 1995
- A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine KinaseScience, 1994
- Peripheral blood stem cell mobilization by cytokinesJournal of Clinical Apheresis, 1992
- α-Interferon therapy of chronic hepatitis B. Current status and recommendationsJournal of Hepatology, 1990
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987